Cargando…

Rare c-KIT c.1926delA and c.1936T>G Mutations in Exon 13 Define Imatinib Resistance in Gastrointestinal Stromal Tumors and Melanoma Patients: Case Reports and Cell Experiments

Background: Target therapies play more and more important roles in gastrointestinal stromal tumors (GISTs) and melanoma with the advancement of clinical drugs that overcome the resistance caused by gene mutations. c-KIT gene mutations account for a large portion of GIST patients, which are known to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Chi, Zhao, Chengzhi, Yang, Ke, Zhou, Hongyan, Jing, Limin, Zhao, Weixing, Dou, Wenguang, Xia, Qingxin, Ma, Jie, Wei, Bing, Guo, Yongjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201753/ https://www.ncbi.nlm.nih.gov/pubmed/35720122 http://dx.doi.org/10.3389/fmolb.2022.730213

Ejemplares similares

Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutations of c-KIT Exon 11
por: NAKANO, Yuko, et al.
Publicado: (2013)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2010)

Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice
por: Lau, Janet, et al.
Publicado: (2014)

Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations
por: Miyake, Kentaro, et al.
Publicado: (2018)

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
por: Catania, Chiara, et al.
Publicado: (2014)

The Frequency of Mutations in Exon 11 of the c-kit Gene in Patients With Leukemia
por: Hussain, Syed Rizwan, et al.
Publicado: (2012)

Mutations in C-KIT exon 11 in canine cutaneous mast cell tumors
por: Neto, Rafael T, et al.
Publicado: (2013)

c.1439delA frameshift deletion mutation in familial adenomatous polyposis
por: Ma, De-Jian, et al.
Publicado: (2018)

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
por: IRIE, Mitsuhiro, et al.
Publicado: (2015)

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
por: Brahmi, Mehdi, et al.
Publicado: (2015)

Identification of Thiazolo[5,4-b]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance
por: Nam, Yunju, et al.
Publicado: (2022)

Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
por: Engin, Gulgun, et al.
Publicado: (2017)

Filaggrin Gene Mutation c.3321delA is Associated with Dry Phenotypes of Atopic Dermatitis in the Chinese Han Population
por: Zhong, Wei-Long, et al.
Publicado: (2016)

Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11
por: Gregory-Bryson, Emmalena, et al.
Publicado: (2010)

Mutations in c‐kit Gene Exons 9 and 13 in Gastrointestinal Stromal Tumors among Japanese
por: Sakurai, Shinji, et al.
Publicado: (2001)

Defining the target and the effect of imatinib on the filarial c-Abl homologue
por: O’Connell, Elise M., et al.
Publicado: (2017)

Analysis of C-Kit Exon 9, Exon 11 and BRAFV600E Mutations Using Sangers Sequencing in Gastrointestinal Stromal Tumours
por: Madhala, Divya, et al.
Publicado: (2020)

Novel Splice Site Mutation in the PROS1 Gene in a Polish Patient with Venous Thromboembolism: c.602-2delA, Splice Acceptor Site of Exon 7
por: Mrożek, Magdalena, et al.
Publicado: (2020)

Vital Statistics, &c., for Five Weeks Ended 31st July, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics. &c., for Five Weeks Ended 30th January, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Five Weeks Ended 30th October, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Four Weeks Ended 28th August, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Four Weeks Ended 25th September, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Four Weeks Ended 27th November, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Four Weeks Ended 26th June, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Four Weeks Ended 25th December, 1926
por: Macgregor, A. S. M.
Publicado: (1927)

Vital Statistics, &c., for Four Weeks Ended 27th March, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Four Weeks Ended 24th April, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics, &c., for Five Weeks Ended 29th May, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Vital Statistics. &c., for Four Weeks Ended 27th February, 1926
por: Macgregor, A. S. M.
Publicado: (1926)

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
por: Zukotynski, Katherine, et al.
Publicado: (2014)

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
por: Alvarez-Twose, Iván, et al.
Publicado: (2016)

Mutations in the TolC Periplasmic Domain Affect Substrate Specificity of the AcrAB-TolC Pump
por: Marshall, Robert L., et al.
Publicado: (2020)

Lechebnaia pedagogika: The Concept and Practice of Therapy in Russian Defectology, c. 1880–1936
por: Byford, Andy
Publicado: (2018)

Bases fundamentales dela exodoncia
por: Villagrán Cruz, Yolanda
Publicado: (1995)

Franciscus Dela Boë Sylvius
por: Dana, Charles L.
Publicado: (1917)

Au-delà des mots
por: Grunfeld, Eva
Publicado: (2022)

Steered Molecular Dynamics Simulations Reveal the Likelier Dissociation Pathway of Imatinib from Its Targeting Kinases c-Kit and Abl
por: Yang, Li-Jun, et al.
Publicado: (2009)

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors
por: Liu, Feiyang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bpfjl7lntdaceqarn7fr8mdgpa